Leaky Gut Syndrome Test: Free Clinical Symptom Screener & Risk Profiler

Your Leaky Gut Risk Score is a weighted composite of symptoms and lifestyle factors associated with compromised intestinal barrier integrity. Higher scores indicate greater co-occurrence of clinical markers linked to intestinal hyperpermeability in peer-reviewed literature. The domain breakdown reveals which physiological systems are most affected.

• Low Risk (0–20%): Minimal indicators of barrier dysfunction detected. Maintain gut-protective habits including diverse fiber intake and probiotic-rich foods.
• Moderate Risk (21–45%): Several markers suggest early-stage permeability changes. Focus on the “Remove” phase of the 4R Protocol to eliminate dietary and pharmacological triggers.
• High Risk (46–70%): Significant symptom clustering across multiple domains warrants clinical evaluation. Consider requesting a lactulose-mannitol permeability test or serum zonulin panel from your provider.
• Very High Risk (71–100%): Your profile strongly correlates with systemic inflammatory patterns seen in documented intestinal hyperpermeability. Consultation with a gastroenterologist or functional medicine practitioner is strongly recommended.

The intestinal epithelial barrier is a single-cell-thick layer held together by tight junction protein complexes — primarily claudin, occludin, and zonula occludens-1 (ZO-1). When these junctions are compromised by triggers such as zonulin upregulation, NSAID-induced mucosal erosion, or dysbiosis-driven inflammation, macromolecules including bacterial lipopolysaccharides (LPS) translocate into the bloodstream, triggering systemic immune activation.

• Zonulin Pathway: Dr. Alessio Fasano’s research identified zonulin as the primary physiological modulator of tight junctions, with gliadin and pathogenic bacteria as two confirmed triggers of its release.
• LPS Translocation: Endotoxemia resulting from bacterial LPS crossing a permeable barrier is measurable via serum LPS-binding protein and correlates with systemic inflammatory markers (CRP, IL-6).
• Gut-Brain Axis: Neuroinflammatory symptoms such as brain fog and mood disturbance are mechanistically linked to vagal afferent signaling and circulating cytokines originating from barrier breach.
• Gut-Skin Axis: Dermatological manifestations (eczema, acne, psoriasis) are associated with immune complex deposition and mast cell activation secondary to antigenic load from intestinal translocation.

Underlying Formula(s): The screener employs a weighted symptom summation model across five clinical domains. Each symptom is assigned a weight of 1–5. The composite score is calculated as:
Risk% = (Σ Domain Scores / Max Possible Score) × 100
Where Max Possible = 80 (GI: 17, Immune: 18, Neuro: 10, Derm: 15, Lifestyle: 20).

Clinical/Scientific Context: Based on the zonulin pathway model described by Dr. Alessio Fasano (Physiological Reviews, 2011) and the Intestinal Permeability Assessment framework from the Institute for Functional Medicine’s 4R Protocol. Symptom weighting reflects diagnostic specificity for intestinal hyperpermeability from clinical literature.

Conditional Logic & Edge Cases: Zero-symptom submissions return an “Insufficient Data” advisory. Scores from lifestyle-only inputs without active symptoms trigger an educational “Risk Factors Present, No Active Symptoms” output. Scores exceeding 71% append explicit gastroenterologist referral language. All autoimmune conditions carry minimum weight of 5 due to strong bidirectional association with barrier dysfunction.

Can this online test replace a clinical intestinal permeability test?
No. This screener identifies symptom patterns associated with increased intestinal permeability but cannot measure barrier function directly. Gold-standard clinical tests include the lactulose-mannitol dual sugar absorption test, serum zonulin levels, and serum LPS-binding protein assays. Use your results as a structured conversation starter with your healthcare provider.

Why are NSAIDs and antibiotics weighted so heavily in the risk score?
NSAIDs directly damage the intestinal mucosa by inhibiting prostaglandin synthesis, which is essential for mucosal blood flow and epithelial repair. Broad-spectrum antibiotics disrupt commensal microbiome populations that maintain tight junction integrity through short-chain fatty acid (SCFA) production, particularly butyrate. Both represent well-documented iatrogenic risk factors for barrier compromise.

What is the 4R Protocol and how does it relate to my results?
The 4R Protocol — Remove, Replace, Reinoculate, Repair — is a sequential therapeutic framework developed within Functional Medicine for restoring intestinal barrier integrity. “Remove” eliminates dietary triggers and pathogenic organisms; “Replace” restores digestive enzymes and HCl; “Reinoculate” reintroduces beneficial microbiota via targeted probiotics; “Repair” supports mucosal healing with nutrients such as L-glutamine, zinc carnosine, and colostrum. Your results highlight which domains to prioritize within this framework.